3 citations
,
September 2016 in “The Journal of Dermatology” A patient with leukemia/lymphoma also had multiple autoimmune diseases, suggesting a link between them.
2 citations
,
June 2024 in “Dermatology” Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.
2 citations
,
May 2024 in “Expert Opinion on Drug Safety” Infections during JAK inhibitor treatment for alopecia areata are usually manageable and rarely stop treatment permanently.
2 citations
,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
2 citations
,
February 2021 in “PubMed” Koilonychia in alopecia areata can improve with oral corticosteroids.
1 citations
,
July 2025 in “Indian Dermatology Online Journal” Certain hair and scalp features indicate a worse outcome in alopecia areata.
1 citations
,
June 2024 in “Cosmoderma” Most patients with alopecia areata in Syria are young adult males, often with patchy scalp hair loss.
1 citations
,
April 2024 in “JAAD International” Adults with alopecia areata stick to their medication better than those with atopic dermatitis.
1 citations
,
December 2020 in “Dermatology Archives” Systemic steroids temporarily improve severe alopecia areata in children but often lead to relapse.
1 citations
,
April 2018 in “Journal of Investigative Dermatology” Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.
January 2026 in “Clinics and Practice” Baricitinib helps alopecia areata and may improve psoriasis, but its effect on psoriatic arthritis is unclear.
January 2026 in “Clinical and Experimental Dermatology” Ruxolitinib helped a patient with alopecia areata regrow hair.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.
June 2025 in “Preprints.org” Baricitinib improves alopecia areata and may help psoriasis but might not be ideal for psoriatic arthritis.
June 2025 in “Patient Preference and Adherence” Chinese patients with alopecia areata value JAK inhibitors but worry about side effects and relapse, highlighting the need for education and support.
March 2025 in “SKIN The Journal of Cutaneous Medicine” Certain patient characteristics can help predict hair regrowth success with ritlecitinib in alopecia areata.
January 2025 in “The Journal of Dermatology” Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
September 2024 in “Journal of the American Academy of Dermatology” Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
July 2024 in “Journal of Investigative Dermatology” Alopecia areata causes negative emotions and stress due to hair loss and emotional triggers.
June 2024 in “JEADV Clinical Practice” Severe alopecia areata patients have a low chance of spontaneous hair regrowth.
April 2024 in “Research Square” IBD patients treated with TNF antagonists may develop autoimmune alopecia areata, with severe cases less likely to improve.
March 2024 in “Dermatology and therapy” AA patients with comorbid conditions face more severe hair loss and need specific treatments.
December 2023 in “Dermatology and therapy” Japanese patients and physicians often disagree on the severity of Alopecia Areata and treatment satisfaction, needing better communication and treatments.
June 2023 in “British journal of dermatology/British journal of dermatology, Supplement” Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.
April 2023 in “Journal of Investigative Dermatology” Patients were very satisfied with the multidisciplinary group visit for alopecia areata.
April 2023 in “Journal of Investigative Dermatology” Patients and doctors often disagree on alopecia areata severity and treatment satisfaction.
May 2017 in “IOSR journal of dental and medical sciences” Both Betasalic ointment and 5% minoxidil are effective and safe for treating Alopecia Areata.
The patient with total hair loss did not regrow hair despite treatment, indicating a poor outlook for this type of hair loss.
5 citations
,
August 1981 in “Archives of Dermatology” Alopecia areata may be caused by the immune system attacking hair follicles.
4 citations
,
January 2013 in “Acta dermato-venereologica” Some patients with Alopecia Areata experience itch due to immune cells and enzymes that cause itching.